Our data clearly pose the question of why SH2B3 loss of function should confer a strong selective advantage to B-ALL, specifically when certain chromosome 21 sequences are highly amplified through complex rearrangements. This evidence concerns the gene SH2B3 and acute lymphoblastic leukemia.